相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia
Jianping Li et al.
CANCER DISCOVERY (2022)
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
Jing-Quan Wang et al.
DRUG RESISTANCE UPDATES (2021)
Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer
Talha Anwar et al.
AMERICAN JOURNAL OF PATHOLOGY (2021)
Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML
Julia M. Kempf et al.
SCIENTIFIC REPORTS (2021)
Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing
Aleksandra Majchrzak-Celinska et al.
GENES (2021)
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
Lingyue Gao et al.
DRUG RESISTANCE UPDATES (2021)
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Jacqulyne P. Robichaux et al.
NATURE (2021)
New RAD51 Inhibitors to Target Homologous Recombination in Human Cells
Irina S. Shkundina et al.
GENES (2021)
Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma
Hiromasa Sakamoto et al.
CANCER MEDICINE (2021)
Loss of KDM6A confers drug resistance in acute myeloid leukemia
Sophie M. Stief et al.
LEUKEMIA (2020)
Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia
Benshang Li et al.
BLOOD (2020)
Further delineation of neuropsychiatric findings in Tatton-Brown-Rahman syndrome due to disease-causing variants in DNMT3A: seven new patients
Jair Tenorio et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Role of epigenetic in leukemia: From mechanism to therapy
Xiao-liang Liu et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2020)
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Xin Cao et al.
DRUG RESISTANCE UPDATES (2020)
Advanced technological tools to study multidrug resistance in cancer
Luca Andrei et al.
DRUG RESISTANCE UPDATES (2020)
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Shannon Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia
Anica M. Wandler et al.
LEUKEMIA (2020)
Impaired cell fate through gain-of-function mutations in a chromatin reader
Liling Wan et al.
NATURE (2020)
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han et al.
BRITISH JOURNAL OF CANCER (2020)
Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia
Luyao Long et al.
DRUG RESISTANCE UPDATES (2020)
EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma
Jessamy Tiffen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Discovering Anti-Cancer Drugs via Computational Methods
Wenqiang Cui et al.
FRONTIERS IN PHARMACOLOGY (2020)
The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia
Joanna Pierro et al.
MOLECULAR CANCER RESEARCH (2020)
Learning from mouse models of MLL fusion gene-driven acute leukemia
Juerg Schwaller
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2020)
SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways
Huairui Yuan et al.
CANCER CELL (2020)
DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy
Jiayu Zhang et al.
CANCERS (2020)
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Sung Choe et al.
BLOOD ADVANCES (2020)
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine
Zhou Tong et al.
BMC MEDICAL GENOMICS (2020)
Mitochondrial chaperone, TRAP1 modulates mitochondrial dynamics and promotes tumor metastasis
Shrikant Purushottam Dharaskar et al.
MITOCHONDRION (2020)
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer
Nhien Tran et al.
MOLECULAR AND CELLULAR BIOLOGY (2020)
Epigenetic Therapies for Cancer
Susan E. Bates
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Nir Shahar et al.
DRUG RESISTANCE UPDATES (2020)
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology
Naama Wiesel-Motiuk et al.
DRUG RESISTANCE UPDATES (2020)
Histone methyltransferase and drug resistance in cancers
Cheng Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer
Wenjing Wang et al.
MOLECULAR CANCER (2020)
Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML
Sheng Li et al.
CANCER DISCOVERY (2020)
Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome
D. G. J. Cucchi et al.
DRUG RESISTANCE UPDATES (2020)
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li et al.
DRUG RESISTANCE UPDATES (2020)
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin et al.
DRUG RESISTANCE UPDATES (2020)
Genetic and epigenetic determinants of diffuse large B-cell lymphoma
Tanner J. Bakhshi et al.
BLOOD CANCER JOURNAL (2020)
A compendium of mutational cancer driver genes
Francisco Martinez-Jimenez et al.
NATURE REVIEWS CANCER (2020)
Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers
Rui Chen et al.
JOURNAL OF CANCER (2020)
Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer
In-Kyu Kim et al.
ONCOGENE (2019)
An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia
Alok Swaroop et al.
ONCOGENE (2019)
Roles of SETD2 in LeukemiaTranscription, DNA-Damage, and Beyond
Anna Skucha et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Helai P. Mohammad et al.
NATURE MEDICINE (2019)
Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors
Mei Han et al.
FRONTIERS IN ONCOLOGY (2019)
SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints
Yunzhu Dong et al.
LEUKEMIA (2019)
Gain-of-Function Mutations: An Emerging Advantage for Cancer Biology
Yongsheng Li et al.
TRENDS IN BIOCHEMICAL SCIENCES (2019)
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML
Cihangir Duy et al.
CANCER DISCOVERY (2019)
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub et al.
FRONTIERS IN ONCOLOGY (2019)
IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells
Geon-Hee Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Haploinsufficiency of NR3C1 drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockage
Haowen Xiao et al.
CANCER CELL INTERNATIONAL (2019)
The multi-factorial nature of clinical multidrug resistance in cancer
Yehuda G. Assaraf et al.
DRUG RESISTANCE UPDATES (2019)
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns
Max Emperle et al.
NUCLEIC ACIDS RESEARCH (2019)
Epigenetic synthetic lethality approaches in cancer therapy
Haoshen Yang et al.
CLINICAL EPIGENETICS (2019)
Mechanisms of acquired tumor drug resistance
Svetlana N. Aleksakhina et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
The histone demethylase UTX/KDM6A in cancer: Progress and puzzles
Wolfgang A. Schulz et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Ensembl 2018
Daniel R. Zerbino et al.
NUCLEIC ACIDS RESEARCH (2018)
Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
Malik Bisserier et al.
BLOOD (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey et al.
CELL (2018)
Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
Philipp A. Greif et al.
CLINICAL CANCER RESEARCH (2018)
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Thorsten Stiewe et al.
DRUG RESISTANCE UPDATES (2018)
Redundant angiogenic signaling and tumor drug resistance
Rajesh N. Gacche et al.
DRUG RESISTANCE UPDATES (2018)
Hallmarks of cancer: The CRISPR generation
Colette Moses et al.
EUROPEAN JOURNAL OF CANCER (2018)
Dexamethasone in hyperleukocytic acute myeloid leukemia
Sarah Bertoli et al.
HAEMATOLOGICA (2018)
Glutathione metabolism in cancer progression and treatment resistance
Ankita Bansal et al.
JOURNAL OF CELL BIOLOGY (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Lynn Quek et al.
NATURE MEDICINE (2018)
Temozolomide-associated hypermutation in gliomas
Serah Choi et al.
NEURO-ONCOLOGY (2018)
DNA mismatch repair in cancer
Marina Baretti et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Dot1 regulates nucleosome dynamics by its inherent histone chaperone activity in yeast
Soyun Lee et al.
NATURE COMMUNICATIONS (2018)
Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma
Eric Hervouet et al.
CLINICAL EPIGENETICS (2018)
Dexamethasone in hyperleukocytic acute myeloid leukemia
Sarah Bertoli et al.
HAEMATOLOGICA (2018)
Human Diseases from Gain-of-Function Mutations in Disordered Protein Regions
Xiao-Han Li et al.
CELL (2018)
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Andrew M. Intlekofer et al.
NATURE (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2018)
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia
Ingrid M. Aries et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation
Weipeng Mu et al.
EPIGENETICS & CHROMATIN (2018)
The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer
Ravi Salgia et al.
TRENDS IN CANCER (2018)
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
D. Morel et al.
ANNALS OF ONCOLOGY (2017)
Dual modulation of MCL-1 and mTOR determines the response to sunitinib
Mohamed Elgendy et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
Stefanie Goellner et al.
NATURE MEDICINE (2017)
The cell cycle checkpoint inhibitors in the treatment of leukemias
A. Ghelli Luserna di Rora et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis
Jonathan J. Ipsaro et al.
PLOS ONE (2017)
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Mark A. Dawson
SCIENCE (2017)
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
Lian Dee Ler et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
Katharine Yen et al.
CANCER DISCOVERY (2017)
Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs
Li Yang et al.
ONCOTARGET (2017)
3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets
Jianjiong Gao et al.
GENOME MEDICINE (2017)
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia
Brenton G. Mar et al.
BLOOD (2017)
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells
Kwon-Ho Song et al.
CANCER RESEARCH (2017)
Drugging the 'undruggable' cancer targets
Chi V. Dang et al.
NATURE REVIEWS CANCER (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
V. Gibaja et al.
ONCOGENE (2016)
Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing
Song Wu et al.
ONCOTARGET (2016)
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Michael M. Gottesman et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56 (2016)
SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia
Jeong-Hyun Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
The pharmacogenomics of drug resistance to protein kinase inhibitors
Nancy K. Gillis et al.
DRUG RESISTANCE UPDATES (2016)
Lysosomes as mediators of drug resistance in cancer
Benny Zhitomirsky et al.
DRUG RESISTANCE UPDATES (2016)
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
Wen Li et al.
DRUG RESISTANCE UPDATES (2016)
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia
Patrick D. Bhola et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
The many faces of histone H3K79 methylation
Zeenat Farooq et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2016)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Joshua D. Campbell et al.
NATURE GENETICS (2016)
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling
Olga A. Guryanova et al.
NATURE MEDICINE (2016)
Targeting the cancer epigenome for therapy
Peter A. Jones et al.
NATURE REVIEWS GENETICS (2016)
MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents
M. Y. Shah et al.
ONCOGENE (2016)
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Xueda Hu et al.
TRENDS IN GENETICS (2016)
Histone Modifications and Cancer
James E. Audia et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance
Alexei Brooun et al.
NATURE COMMUNICATIONS (2016)
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Ludovica Morera et al.
CLINICAL EPIGENETICS (2016)
Metabolic control of epigenetics in cancer
Adam Kinnaird et al.
NATURE REVIEWS CANCER (2016)
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Sophia X. Pfister et al.
CANCER CELL (2015)
Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention
Chen Shen et al.
CURRENT OPINION IN ONCOLOGY (2015)
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Michael Juchum et al.
DRUG RESISTANCE UPDATES (2015)
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Yoav Binenbaum et al.
DRUG RESISTANCE UPDATES (2015)
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers
Yoshinaga Okugawa et al.
GASTROENTEROLOGY (2015)
Somatic mutation in cancer and normal cells
Inigo Martincorena et al.
SCIENCE (2015)
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas
M. A. Lunning et al.
BLOOD CANCER JOURNAL (2015)
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors
Theresa Baker et al.
ONCOTARGET (2015)
Somatic cancer mutations in the MLL3-SET domain alter the catalytic properties of the enzyme
Sara Weirich et al.
CLINICAL EPIGENETICS (2015)
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Andrew Kernytsky et al.
BLOOD (2015)
Cancer Evolution: Mathematical Models and Computational Inference
Niko Beerenwinkel et al.
SYSTEMATIC BIOLOGY (2015)
Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance
Shigeo Ohba et al.
CANCER RESEARCH (2014)
Development and Applications of CRISPR-Cas9 for Genome Engineering
Patrick D. Hsu et al.
CELL (2014)
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Lev M. Kats et al.
CELL STEM CELL (2014)
Expanding the SRI domain family: A common scaffold for binding the phosphorylated C-terminal domain of RNA polymerase II
Joseph Rebehmed et al.
FEBS LETTERS (2014)
Emerging role of nanog in tumorigenesis and cancer stem cells
Luis E. I. V. Santaliz-Ruiz et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Phosphoproteomics Screen Reveals Akt Isoform-Specific Signals Linking RNA Processing to Lung Cancer
Ioannis Sanidas et al.
MOLECULAR CELL (2014)
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies
J. A. Oyer et al.
LEUKEMIA (2014)
Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia
Brenton G. Mar et al.
NATURE COMMUNICATIONS (2014)
Influence of Metabolism on Epigenetics and Disease
William G. Kaelin et al.
CELL (2013)
The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα
Feng Li et al.
CELL (2013)
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Shivani Garapaty-Rao et al.
CHEMISTRY & BIOLOGY (2013)
Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality
Annemie A. Van Linden et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
Irfan A. Asangani et al.
MOLECULAR CELL (2013)
Chromatin proteins and modifications as drug targets
Kristian Helin et al.
NATURE (2013)
Mining the epigenetic landscape in ALL
Lindsay M. LaFave et al.
NATURE GENETICS (2013)
Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation
Manuela Delvecchio et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations
Hong Wu et al.
PLOS ONE (2013)
The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe
Richard J. Epstein
FRONTIERS IN ONCOLOGY (2013)
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
Jueng Soo You et al.
CANCER CELL (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Roel H. Wilting et al.
DRUG RESISTANCE UPDATES (2012)
Drug resistance: Still a daunting challenge to the successful treatment of AML
Brian C. Shaffer et al.
DRUG RESISTANCE UPDATES (2012)
Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance
Yuejun Fu et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia
A. Inthal et al.
LEUKEMIA (2012)
Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia
C. C. Porter et al.
LEUKEMIA (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Peter Bouwman et al.
NATURE REVIEWS CANCER (2012)
Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
Kristy J. Gotink et al.
CLINICAL CANCER RESEARCH (2011)
CREBBP mutations in relapsed acute lymphoblastic leukaemia
Charles G. Mullighan et al.
NATURE (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-κB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis
Arthur Kwok Leung Cheung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition
Petra S. Bachmann et al.
BLOOD (2010)
Histone Methyltransferase Gene SETD2 Is a Novel Tumor Suppressor Gene in Clear Cell Renal Cell Carcinoma
Gerben Duns et al.
CANCER RESEARCH (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Global Analysis of H3K4 Methylation Defines MLL Family Member Targets and Points to a Role for MLL1-Mediated H3K4 Methylation in the Regulation of Transcriptional Initiation by RNA Polymerase II
Pengfei Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator
Xin Liu et al.
NATURE (2008)
Transforming pathways unleashed by a HDAC2 mutation in human cancer
S. Ropero et al.
ONCOGENE (2008)
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
S Ropero et al.
NATURE GENETICS (2006)
The Polycomb group protein EZH2 directly controls DNA methylation
E Viré et al.
NATURE (2006)
Solution structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction with the hyperphosphorylated C-terminal domain of Rpb1
M Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Structure of the catalytic domain of human DOT1L, a Non-SET domain nucleosomal histone methyltransferase
JR Min et al.
CELL (2003)
分享论文
